SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
DECLARATION OF POSTAL BALLOT RESULTS & SCRUTINIZERS REPORT WITH RESPECT TO INCREASE OF AUTHORIZED SHARE CAPITAL OF THE COMPANY31-07-2023
31-07-2023
SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Launches Pemetrexed Injection (10 Ml, 50 Ml, 85 Ml, And 100 Ml Sizes) In India Under The Brand Name VRTU(r)
This is to inform that the company has received approval from CDSCO, New Delhi for the manufacturing and sale of first time in the world Pemetrexed Ready to use injections 10 ml, 50ml, 85ml and 100 ml in India. Shilpa will commercialize the product under the brand name VRTU. VRTU 10ml, 50ml, 85ml and 100 ml will be launched immediately. Shilpa Medicare Limited is the first company to receive approval for manufacturing and Market of Pemetrexed injection 10ml, 50 ml, 85 ml, and 100 ml in India for treatment of metastatic Non-squamous Non small cell lung cancer and Mesothelioma in conjunction with cisplatin. A substantial advancement in cancer therapy has been made with this crucial milestone giving patients and medical professionals fresh hope.31-07-2023
SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Seeking approval of members of the Company pursuant to Section 180 (1)(a) of the Companies Act and other applicable regulations.29-07-2023
SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Board Meeting Outcome
Outcome of the meeting of Board of Directors held on 21 July 202321-07-2023
SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, Please find enclosed a certificate dated 5 July 2023 for the quarter ended 30 June 2023 , certifying the details of securities dematerialized/ rematerialized during the aforesaid period were maintained by "M/s Kfin Technologies Limited" (SEBI Registration No INR000000221) , the registrar and share transfer agent of Shilpa Medicare Limited.11-07-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication - Postal Ballot Notice04-07-2023
SHILPA MEDICARE LTD. - 530549 - Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pivotal Enterprises Pvt Ltd & Others04-07-2023
SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pivotal Enterprises Pvt Ltd & PACs03-07-2023
SHILPA MEDICARE LTD. - 530549 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Shilpa Biologicals (Wholly owned Subsidiary of Shilpa Medicare Limited) has received the Marketing Authorization permission for its Adalimumab 40 mg/ 0.4 ml Injection in prefilled syringe.29-06-2023
SHILPA MEDICARE LTD. - 530549 - Announcement Under Regulation 30 Of SEBI (LODR) 2015
Shilpa Medicare Limited Launches Lenvatinib Capsules (12mg, 18mg & 24 mg) in India under the brand name Lenshil29-06-2023